CAS: 1299440-37-1 - Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer
Formel:Unspecified
- Synonyme:
- Uplizna
- Inebilizumab-cdon
- Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer
- Inebilizumab
- MEDI 551
| Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
|---|---|---|---|---|
 | Inebilizumab REF: TM-T76713CAS: 1299440-37-1 | SDS-PAGE:99.3%;SEC-HPLC:96.2% | 184,00 €~2.135,00 € | Di 15 Okt 24 |
 | Inebilizumab REF: 3D-CLA1393CAS: 1299440-37-1 | - - - | Nachfragen | Fr 25 Okt 24 |
Inebilizumab
CAS:1299440-37-1
Inebilizumab: humanized anti-CD19 antibody, enhances cytotoxicity against B cells, treats autoimmune diseases like MS.
Reinheit:
SDS-PAGE:99.3%;SEC-HPLC:96.2%
Farbe und Form:
Solid
Molekulargewicht:
Approximately 146.60 kDa
Ref: TM-T76713
| 1mg | 184,00 € | ||
| 5mg | 480,00 € | ||
| 10mg | 770,00 € | ||
| 25mg | 1.175,00 € | ||
| 50mg | 1.570,00 € | ||
| 100mg | 2.135,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 15. Oktober 2024
Inebilizumab
CAS:1299440-37-1
Anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cell.
Ref: 3D-CLA1393
| Unbestimmte Größe | Nachfragen |
Voraussichtliche Lieferung in Vereinigte Staaten, am Freitag 25. Oktober 2024
